Neuro-Oncology · 2012 · 161 citations · 48 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyImmune Cell InfiltrationRegulatory T CellsT Cell BiologyTumor Immune MicroenvironmentTumor-infiltrating LymphocytesCancer-associated ImmunosuppressionCd4 Positive T CellsGlioblastoma ImmunologyGlioblastoma ImmunotherapyPro-apoptotic BalanceRegulatory T Cell RecruitmentSoluble MediatorsTumor Microenvironment Effects
In patients with glioma, the tumor microenvironment can significantly impact pro-inflammatory immune cell functions. However, the mechanisms by which this occurs are poorly defined. Because immunosuppressive regulatory T cells (Treg) are over represented in the tumor microenvironment compared with peripheral blood, we hypothesized that the tumor may have an effect on Treg survival, migration, expansion, and/or induction of a regulatory phenotype from non-Treg conventional CD4+ T cells. We defined the impact of soluble factors produced by tumor cells on Treg from healthy patients in vitro to determine mechanisms by which gliomas influence T cell populations. We found that tumor-derived soluble factors allowed for preferential proliferation and increased chemotaxis of Treg, compared with conventional T cells, indicating that these mechanisms may contribute to the increased Treg in the tumor microenvironment. Conventional T cells also exhibited a significantly increased expression of pro-apoptotic transcripts in the presence of tumor-derived factors, indicating that survival of Treg in the tumor site is driven by exposure to soluble factors produced by the tumor. Together, these data suggest that tumor burden may induce increased Treg infiltration, proliferation, and survival, negating productive anti-tumor immune responses in patients treated with immunotherapies. Collectively, our data indicate that several mechanisms of Treg recruitment and retention in the tumor microenvironment exist and may need to be addressed to improve the specificity of immunotherapies seeking to eliminate Treg in patients with glioma.
48
Cancer immunotherapy: moving beyond current vaccines
Steven A. Rosenberg, James C. Yang, Nicholas P. Restifo · Nature Medicine · 2004 · 3K citations · Full text
Medicine, Immunology, Oncology +14
Statistical analysis of real-time PCR data
Joshua S. Yuan, Ann M. Reed, Feng Chen et al. · BMC Bioinformatics · 2006 · 2.2K citations · Full text
Michael A. Curran, Welby Montalvo, Hideo Yagita∥ et al. · Proceedings of the National Academy of Sciences · 2010 · 1.9K citations · Full text
Life Sciences, Immunology, Oncology +17
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa, James S. Waldron, Amith Panner et al. · Nature Medicine · 2006 · 1.4K citations
Medicine, Cancer Biology, Oncology +14